| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| Other Sizes |
| Targets |
As a stable isotope-labeled endogenous metabolite, Propane-1,2,3-triyl tripalmitate-d31 does not have a specific pharmacological target. It is used to study lipid metabolism and the role of triglycerides in various biological processes. The compound is classified as an Isotope-Labeled Compound.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Propane-1,2,3-triyl tripalmitate-d31 is used in vitro as a tracer to study lipid metabolism and triglyceride hydrolysis. The compound is added to cell culture media to track fatty acid uptake, incorporation into lipids, and metabolic fate. Stable heavy isotopes have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. |
| ln Vivo |
In vivo, Propane-1,2,3-triyl tripalmitate-d31 is used in metabolic studies to trace triglyceride absorption, distribution, metabolism, and excretion. The deuterium label allows for precise quantification of the compound and its metabolites in biological fluids and tissues using mass spectrometry.
|
| Enzyme Assay |
As an analytical standard, Propane-1,2,3-triyl tripalmitate-d31 is used in lipidomics studies. Typical protocols involve spiking the labeled compound into samples prior to extraction and analysis by LC-MS. The compound serves as an internal standard to correct for matrix effects and instrument variability. The labeled compound co-elutes with the unlabeled analyte but is detected at a different mass-to-charge ratio.
|
| Cell Assay |
In vitro cell culture experiments using Propane-1,2,3-triyl tripalmitate-d31 involve treating cells with the labeled triglyceride and analyzing its uptake and metabolism by mass spectrometry. The compound can be used to study lipid metabolism, fatty acid oxidation, and triglyceride hydrolysis in various cell types. Concentrations and incubation times vary depending on the experimental design.
|
| Animal Protocol |
In vivo animal studies using Propane-1,2,3-triyl tripalmitate-d31 involve administering the compound to rodents via oral gavage or intravenous injection. Blood samples are collected at various time points, and the concentration of the labeled compound and its metabolites is measured by mass spectrometry. Tissue distribution studies can also be performed.
|
| ADME/Pharmacokinetics |
Propane-1,2,3-triyl tripalmitate-d31 exhibits pharmacokinetic properties similar to those of unlabeled triglycerides. As a triacylglycerol, it is hydrolyzed by lipases in the gastrointestinal tract and absorbed as free fatty acids and monoacylglycerols. The compound is metabolized via beta-oxidation and incorporated into lipid stores. The deuterium label provides a distinct mass shift for analytical detection.
|
| Toxicity/Toxicokinetics |
Propane-1,2,3-triyl tripalmitate-d31 is considered safe for research use at typical concentrations. As an endogenous metabolite, the unlabeled compound is naturally present in the body. The compound is stable under recommended storage conditions. As a stable isotope-labeled compound, it is not intended for therapeutic use and is handled under standard laboratory safety practices.
|
| References | |
| Additional Infomation |
Propane-1,2,3-triyl tripalmitate is an endogenous metabolite that serves as a major storage form of fatty acids in adipose tissue. The deuterated form is used as a tracer to study lipid metabolism and the pharmacokinetics of triglyceride-based drug delivery systems. The compound is typically stored at -20°C and is stable for extended periods under recommended conditions.
|
| Molecular Formula |
C51H5D93O6
|
|---|---|
| Molecular Weight |
900.89
|
| Exact Mass |
900.32
|
| CAS # |
241157-04-0
|
| Related CAS # |
Propane-1,2,3-triyl tripalmitate;555-44-2
|
| PubChem CID |
71308996
|
| Appearance |
White to off-white solid powder
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
759.8±27.0 °C at 760 mmHg
|
| Melting Point |
64-66ºC(lit.)
|
| Flash Point |
286.1±23.8 °C
|
| Vapour Pressure |
0.0±2.6 mmHg at 25°C
|
| Index of Refraction |
1.465
|
| LogP |
22.08
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
50
|
| Heavy Atom Count |
57
|
| Complexity |
798
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C(=O)OCC(COC(=O)C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])OC(=O)C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H]
|
| InChi Key |
PVNIQBQSYATKKL-JGBASCRPSA-N
|
| InChi Code |
InChI=1S/C51H98O6/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-49(52)55-46-48(57-51(54)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)47-56-50(53)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h48H,4-47H2,1-3H3/i1D3,2D3,3D3,4D2,5D2,6D2,7D2,8D2,9D2,10D2,11D2,12D2,13D2,14D2,15D2,16D2,17D2,18D2,19D2,20D2,21D2,22D2,23D2,24D2,25D2,26D2,27D2,28D2,29D2,30D2,31D2,32D2,33D2,34D2,35D2,36D2,37D2,38D2,39D2,40D2,41D2,42D2,43D2,44D2,45D2
|
| Chemical Name |
2,3-bis(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-hentriacontadeuteriohexadecanoyloxy)propyl 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,16,16,16-hentriacontadeuteriohexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1100 mL | 5.5501 mL | 11.1001 mL | |
| 5 mM | 0.2220 mL | 1.1100 mL | 2.2200 mL | |
| 10 mM | 0.1110 mL | 0.5550 mL | 1.1100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
